Explore All 3110 Add-on Acquisition Life Science Deals - Search the Database Free
M&A Deal Summary |
|
|---|---|
| Date | September 17, 2008 |
| Target | Prestwick Pharmaceuticals |
| Sector | Life Science |
| Buyer(s) | Biovail |
| Deal Type | Add-on Acquisition |
FILTER BY
Biovail Corp. is a specialty pharmaceutical company engaged in the formulation, clinical testing, registration, manufacture, and commercialization of pharmaceutical products. The Company is focused on the development and commercialization of medicines that address unmet medical needs in niche specialty central nervous system (CNS) markets.
| Deal Context for Buyer | # |
|---|---|
| Overall | 1 of 3 |
| Sector: Life Science | 1 of 3 |
| Type: Add-on Acquisition | 1 of 1 |
| State: District of Columbia | 1 of 1 |
| Country: United States | 1 of 3 |
| Year: 2008 | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2009-05-06 |
GlaxoSmithKline - Wellbutrin XL
United States GlaxoSmithKline plc - Wellbutrin XL which is indicated for the treatment of major depressive disorder and seasonal affective disorder, was developed and is manufactured by Biovail and has been distributed by GSK in the United States since September 2003. |
Buy | $510M |
